Journal article icon

Journal article

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Abstract:

OBJECTIVE: To establish the safety and efficacy of repeat infusions of tocilizumab (previously known as MRA), a humanized anti-interleukin-6 (IL-6) receptor antibody, alone and in combination with methotrexate (MTX), for the treatment of rheumatoid arthritis (RA). METHODS: The study group comprised 359 patients with active RA in whom the response to MTX was inadequate. During a stabilization period, these patients received their current dose of MTX for at least 4 weeks. Following stabilizati...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/art.22033

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Expand authors...
Journal:
Arthritis and rheumatism
Volume:
54
Issue:
9
Pages:
2817-2829
Publication date:
2006-09-05
DOI:
EISSN:
1529-0131
ISSN:
0004-3591
URN:
uuid:0da5a0b1-ae7c-4559-9773-5e80008da95a
Source identifiers:
226825
Local pid:
pubs:226825

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP